Edwin O’Connor, a partner in Goodwin’s Life Sciences group, has a broad-based capital markets practice and represents issuers and underwriters in public and private corporate finance transactions, both in the United States and internationally. His experience encompasses initial public offerings, follow-on equity offerings, investment grade, high-yield and convertible debt offerings and offerings of preferred, hybrid and derivative securities. He has particular experience with capital markets transactions in the tech, life sciences and clean tech sectors.





Mr. O’Connor’s recent representations include:

  • The underwriters in Altair Engineering’s $156 million initial public offering
  • Deciphera Pharmaceuticals in its $127.5 million initial public offering
  • The underwriters in Arsanis’ $40 million initial public offering 
  • argenx NV in its $100 million initial public offering and $266 million public follow-on offering
  • The underwriters in G1 Therapeutics’ $116 million initial public offering
  • The underwriters in Ovid Therapeutics’ $75 million initial public offering
  • The underwriter in BeyondSpring’s $54 million initial public offering
  • The underwriters as joint book-running managers in Albireo Pharmas’ $45 million follow-on public offering
  • The underwriters in Syndax Pharmaceuticals’ $50 million follow-on public offering
  • BeiGene in its $158 million initial public offering and $200 million and $800 million follow-on public offerings
  • The underwriters in a $40 million follow-on offering for Innocoll
  • The underwriters in Reata Pharmaceuticals' $60.5 million initial public offering
  • The underwriters in Oncobiologics' $35 million initial public offering
  • Voyager Therapeutics in its $70 million initial public offering
  • The underwriters in the $281.5 million follow-on offering for DBV Technologies
  • The underwriters in a $162 million secondary public offering by existing shareholders for Horizon Pharma, Inc.
  • Inotek Pharmaceuticals Corporation in its $40 million initial public offering and a concurrent offering of $20 million offering of convertible senior notes, its $69 million follow-on offering, its $50 million offering of convertible senior notes, and its sale to Rocket Pharmaceuticals
  • The underwriters in Trinseo’s $190 million initial public offering*
  • The underwriters in Paycom Software’s $100 million initial public offering*

As Vice President in Goldman Sachs’ Investment Banking Division, Mr. O’Connor advised on several initial public offerings, including:

  • Cornerstone OnDemand’s $137 million IPO
  • RPX’s $160 million IPO
  • Gigamon’s $128.5 million IPO
  • Jive’s $120 million IPO
  • Palo Alto Network’s $260 million IPO

* Denotes experience prior to joining Goodwin

Professional Experience

Prior to joining Goodwin in 2014, Mr. O’Connor practiced at Gibson, Dunn & Crutcher. Previously, he was a vice president in the Investment Banking Division of Goldman, Sachs & Co., where he was responsible for the execution of equity and equity-linked offerings across all industry sectors. While at Goldman, Mr. O’Connor was also a vice president, associate general counsel in the Investment Banking Division’s Legal Group. At Goldman, he worked on transactions occurring in a number of geographies, including New York, Silicon Valley, London and Hong Kong. Before joining Goldman, he was an associate at Davis Polk & Wardwell in New York and in London.


In law school, Mr. O’Connor served as comments editor of The Journal of International Economic Law.

In The News









J.D., 1998
University of Pennsylvania Law School
B.A., Economics, 1995
Colgate University
(magna cum laude; Phi Beta Kappa)



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique